| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Gastroenteropancreatic neuroendocrine tumors in 2025: From molecular profiling to artificial intelligence-driven therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Marcio J Concepción-Zavaleta, Jenyfer M Fuentes-Mendoza, José Paz-Ibarra, Luis A Concepción-Urteaga, Jeny Justina Mendoza-Godoy, Jhean G Gonzáles-Yovera, Juan Eduardo Quiroz-Aldave, Frederick Massucco-Revoredo, Augusto Aldave-Herrera and Regina Aquino-Salverredy |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Marcio J Concepción-Zavaleta, Grupo de Investigación en Neurociencias, Metabolismo, Efectividad Clínica y Salud Pública, Universidad Científica del Sur, 19 Panamericana Sur Km, Villa El Salvador, Lima 15072, Peru. mconcepcion@cientifica.edu.pe |
| Key Words |
Gastroenteropancreatic neuroendocrine tumors; Precision medicine; Molecular profiling; Artificial intelligence; Theranostic imaging; Liquid biopsy biomarkers; Targeted therapies |
| Core Tip |
Gastroenteropancreatic neuroendocrine tumors exhibit marked biological and clinical heterogeneity that extends beyond traditional histological classification. While molecular features distinguishing well-differentiated neuroendocrine tumors from poorly differentiated carcinomas provide a critical biological framework, they represent only one dimension of disease complexity. This review highlights how the integration of molecular profiling, artificial intelligence–based analytics, radiomics, liquid biopsy biomarkers (including NETest 2.0), and theranostic imaging enables a more comprehensive and dynamic approach to diagnosis, risk stratification, and therapeutic decision-making. An integrative precision medicine model is proposed to address tumor heterogeneity and support individualized, data-driven management strategies across the full spectrum of gastroenteropancreatic neuroendocrine tumors. |
| Publish Date |
2026-03-12 12:25 |
| Citation |
Concepción-Zavaleta MJ, Fuentes-Mendoza JM, Paz-Ibarra J, Concepción-Urteaga LA, Mendoza-Godoy JJ, Gonzáles-Yovera JG, Quiroz-Aldave JE, Massucco-Revoredo F, Aldave-Herrera A, Aquino-Salverredy R. Gastroenteropancreatic neuroendocrine tumors in 2025: From molecular profiling to artificial intelligence-driven therapy. World J Gastrointest Oncol 2026; 18(3): 114205 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i3/114205.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i3.114205 |
